retatrutide news recency 3 produces up to 30.3% weight loss in Phase trial Retatrutide Results: 24% Weight Loss

WueestSLaesserCIBoni-SchnetzlerMItemFLucchiniFCBorsigovaMet al

Orforglipron, a non-peptide GLP-1 receptor agonist, represents another daily oral incretin-based AOM displaying dose-dependent BW and WC reductions at 36 weeks ranging from 9.4 to 14.7% and from 9.6 cm to 13.6 cm with the 12 and 45 mg dose, respectively, in mostly female (59%) patients with a mean age of 54.2 years and BMI 37.9 kg/m 2 44

CagriSema (from Novo Nordisk) combines cagrilintide and semaglutide in a single injection

Clinical data has shown up to 22.5 percent body weight reduction in study participants

This hormone helps regulate blood sugar and satiety by slowing down digestion, promoting insulin release, and reducing appetite

We asked the Anesthesia Manual App: Should GLP-1R agonists be stopped preoperatively?